TNF inhibitors, which were among the first biologics widely adopted for IBD, have been examined for increased risk of melanoma and NMSC [12], but studies have often been limited by confounding factors such as prior or concurrent thiopurine use and insufficient statistical power. The gene discussed is TNF; the disease is melanoma.